Patricia Van Arnum reports in her PharmTech Talk article, Contract Manufacturers: Watch Out for a Bumpy Ride, "the troubling conditions of the US economy as a whole and the resulting curtailment in financing and credit was hurting an important customer base for CMOs: emerging pharmaceutical companies." As I see it, the economy continues to crater, and there doesn't seem to be any particular industry sector immune to the current state of the economy. Although the stats cited in the article indicate otherwise, as a stock holder of some pharma stocks, I remain hopeful and optimistic for a rapid economic recovery.
Return Home: http://drughealth.blogspot.com/
Posts
No comments:
Post a Comment